Is your billion-dollar oncology artificial intelligence (AI) cutting-edge technology, or is it artificial ignorance? That’s the question Frederick National Laboratory’s Maggie Scully, Ph.D., and a panel of industry experts seek to tackle at the BIO International Convention in Boston on June 7.
Karim Budhwani, Ph.D., DLA, CEO-scientist of CerFlux, Inc., who will be moderating the panel, noted that the rapid pace of AI has scared many.
“They want to pause,” he said. “You cannot pause AI in oncology, instead we must accelerate it.”
The American Cancer Society estimates that every day 1,671 people in the United States die from cancer. As researchers look to use all tools at their disposal to reduce this toll, Budhwani organized this panel to discuss how to ensure AI positively shapes the future for cancer drug discovery and precision medicine.
It is up to us to make sure this potential is met with true benefit for all.
The panelists will also discuss the many challenges and opportunities along the way, from research and development to regulatory processes.
“These dialogues are extremely important in how we shape this landscape,” Budhwani said, “because there is no mistaking that we will shape the landscape.”
In addition to Budhwani and Scully, the panel will also include Sandeep Menon, Ph.D., chief scientific officer of AI and Digital Science at Pfizer, and Tahera Kan, M.B.A., M.S., vice president of Precision Medicine and Enabling Technology at Johnson & Johnson.
As the non-industry representative on the panel, Scully, who is the FNL’s partnership development manager, hopes to bring a different perspective to the table, specifically advocating for partnership and training in the AI space.
“Applying AI has tremendous potential in our fight against cancer, from improving screening to predicting treatment outcomes,” Scully said. “To bolster that potential, the field has seen innovative partnership models and training activities targeting previously untapped talent pools. It is up to us to make sure this potential is met with true benefit for all.”
This panel is just one of seven panels on oncology at the BIO International Convention, an annual event that attracts more than 14,000 biotechnology and pharmaceutical leaders from around the world. If you will be attending BIO, make sure to join the panel at 11:00 AM EDT on June 7 in session room 254A.
Meet the FNL partnership team
FNL will also have a booth in the Federal Laboratory Consortium for Technology Transfer pavilion (booth #3575). Representatives from the FNL’s Center for Innovation and Strategic Partnerships will be available for one-on-one meetings to discuss how industry, government, academia and nonprofits can partner with the FNL on biomedical research.
Media Inquiries
Mary Ellen Hackett
Manager, Communications Office
301-401-8670